- Home
- » Tags
- » Ganciclovir
Top View
- Tenofovir Disoproxil Fumarate Fixed-Dose Combination
- Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
- Letermovir Guideline
- R Hegmatogenous Retinal Detachment in Cytomegalovirus
- Viral Infections Randomized Clinical Trial of Ganciclovir Vs Acyclovir for Prevention of Cytomegalovirus Antigenemia After Allogeneic Transplantation
- Valganciclovir—Ganciclovir Use and Systematic Therapeutic Drug Monitoring
- Intravenous Ganciclovir Cause? What Should You Do About Them? Central Vein (E.G
- ICCB-L Plate (10 Mm / 3.33 Mm) ICCB-L Well Vendor ID Chemical Name
- SYMTUZA® (Darunavir, Cobicistat, Emtricitabine, and Tenofovir
- Nephrotoxicity of Acyclovir and Ganciclovir in Rats: Evaluation of Glomerular Hemodynamics
- Randomised Trial of Ganciclovir and Acyclovir in Br J Ophthalmol: First Published As 10.1136/Bjo.80.2.140 on 1 February 1996
- VALCYTE Prescribing Information
- Medication Guidelines for Solid Organ Transplants
- Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: a Matched Cohort Study
- VIREAD® (Tenofovir
- Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2019
- Vemlidy, INN-Tenofovir Alafenamide
- Cytomegalovirus, Congenital
- Truvada (Emtricitabine Tenofovir Disoproxil
- Prevymis (Letermovir) C15922-A
- Guidelines for the Use of Ganciclovir (Cytovene )
- Human Herpesvirus-6 Dnaemia in Immunosuppressed Adult Patients with Leukemia at Risk for Mold Infection Roy F
- A Prospective, Randomised, Open-Label Phase
- GANCICLOVIR Capsulesrx Onlyfor ORAL ADMINISTRATION
- Letermovir Salvage for Complicated Cases of Resistant
- Guidelines for ATC Classification and DDD Assignment 2021
- Viral Infections High-Dose Acyclovir and Pre-Emptive Ganciclovir To
- Oral Valganciclovir As Pre-Emptive Therapy Has Similar Efficacy On
- Viread, INN-Tenofovir Disoproxil Fumarate
- Effectiveness of Ganciclovir Against Human Herpesvirus-6 Excreted in Saliva in Stem Cell Transplant Recipients
- [2016]. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016
- Pharmacokinetics of Long-Acting Tenofovir Alafenamide (GS-7340
- Treatment Guideline for Infants with Congenital CMV Disease (Ccmv)
- Ganciclovir (As Ganciclovir Sodium)
- 2013 March (127): Treatment Guidelines
- BIKTARVY Safely and Effectively
- Baraclude, INN-Entecavir
- Guidelines for ATC Classification and DDD Assignment 2013
- VALCYTE™™ (Valganciclovir Hydrochloride Tablets) WARNING
- Tenofovir Prodrugs Potently Inhibit Epstein–Barr Virus Lytic DNA Replication by Targeting the Viral DNA Polymerase
- Viread, INN-Tenofovir Disoproxil Fumarate
- Interferons As Therapeutic Agents in Infectious Diseases Mckenzie C
- Exploring the Selectivity of Guanine Scaffold in Anticancer Drug
- GANCICLOVIR INJECTION Label
- 10 Ganciclovir and Valganciclovir Use in Children
- Letermovir for Cytomegalovirus Prophylaxis in Lung Transplant Patients with Valganciclovir-Induced Leukopenia
- Case Report Successful Treatment of Human Herpesvirus-6 Encephalitis After Bone Marrow Transplantation
- 050298 Failure of Cytarabine in Progressive Multifocal
- Central Nervous System Complications Due to Human Herpesvirus 6 Infection in Pediatric Age Group
- Application for Inclusion of Tenofovir Alafenamide (Vemlidy®) Tablets on the WHO Model List of Essential Medicines
- VEMLIDY® (Tenofovir Alafenamide) Tablets, for Oral Use Initial U.S
- Review of Cytomegalovirus Prevention and Treatment Strategies